A new Medicare initiative set to launch next month will allow eligible seniors to access popular weight-loss medications for as little as $50 per month, potentially triggering a surge in demand for treatments such as Wegovy and Zepbound.

Healthcare experts expect millions of Medicare beneficiaries who previously found these drugs too expensive to seek prescriptions once the program begins. The anticipated influx of patients could place additional strain on doctors' offices, obesity specialists and primary care providers already facing staffing shortages and heavy workloads.

The rollout is being viewed as one of the largest expansions of access to weight-loss medications in U.S. history. While supporters say the program could improve health outcomes for seniors struggling with obesity, concerns remain about whether healthcare providers can keep pace with growing demand for consultations, monitoring and ongoing treatment.

As enrollment opens, the success of the program may depend not only on drug availability but also on the healthcare system's ability to manage a wave of new patients seeking access to these highly sought-after medications.